Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ABL2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ABL2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ABL2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ABL2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ABL2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ABL2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ABL2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ABL2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ABL2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:00315328 | Cervix | CC | actin cytoskeleton reorganization | 31/2311 | 107/18723 | 3.34e-06 | 8.99e-05 | 31 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
GO:00465785 | Cervix | CC | regulation of Ras protein signal transduction | 44/2311 | 189/18723 | 2.05e-05 | 3.73e-04 | 44 |
GO:00301008 | Cervix | CC | regulation of endocytosis | 47/2311 | 211/18723 | 3.65e-05 | 5.82e-04 | 47 |
GO:20002493 | Cervix | CC | regulation of actin cytoskeleton reorganization | 14/2311 | 39/18723 | 1.36e-04 | 1.66e-03 | 14 |
GO:00105067 | Cervix | CC | regulation of autophagy | 61/2311 | 317/18723 | 2.61e-04 | 2.87e-03 | 61 |
GO:00350235 | Cervix | CC | regulation of Rho protein signal transduction | 22/2311 | 86/18723 | 5.93e-04 | 5.60e-03 | 22 |
GO:00510585 | Cervix | CC | negative regulation of small GTPase mediated signal transduction | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
GO:00350244 | Cervix | CC | negative regulation of Rho protein signal transduction | 8/2311 | 22/18723 | 3.43e-03 | 2.22e-02 | 8 |
GO:00465804 | Cervix | CC | negative regulation of Ras protein signal transduction | 13/2311 | 49/18723 | 5.34e-03 | 3.10e-02 | 13 |
GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
GO:0010506 | Colorectum | AD | regulation of autophagy | 111/3918 | 317/18723 | 3.57e-09 | 2.35e-07 | 111 |
GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABL2 | SNV | Missense_Mutation | novel | c.3062N>A | p.Gly1021Glu | p.G1021E | P42684 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.756) | TCGA-CR-7390-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | novel | c.3352G>T | p.Asp1118Tyr | p.D1118Y | P42684 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.978) | TCGA-CR-7402-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
ABL2 | SNV | Missense_Mutation | novel | c.3049N>C | p.Glu1017Gln | p.E1017Q | P42684 | protein_coding | tolerated_low_confidence(0.54) | benign(0.013) | TCGA-CV-7089-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | novel | c.2207N>T | p.Gly736Val | p.G736V | P42684 | protein_coding | deleterious_low_confidence(0.02) | benign(0.001) | TCGA-CV-7261-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | novel | c.2530N>T | p.Ser844Cys | p.S844C | P42684 | protein_coding | tolerated_low_confidence(0.07) | benign(0.062) | TCGA-F7-A61W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | novel | c.1001N>A | p.Ala334Glu | p.A334E | P42684 | protein_coding | deleterious(0.02) | benign(0.282) | TCGA-UF-A71D-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | | c.3190N>T | p.Gly1064Cys | p.G1064C | P42684 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.961) | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | | c.1034N>C | p.Val345Ala | p.V345A | P42684 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | | c.996N>C | p.Glu332Asp | p.E332D | P42684 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
ABL2 | SNV | Missense_Mutation | | c.551N>G | p.Glu184Gly | p.E184G | P42684 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | DASATINIB | DASATINIB | |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | inhibitor | TOZASERTIB | TOZASERTIB | 19035792 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | PONATINIB | PONATINIB | 20513156 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | DASATINIB | DASATINIB | |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | DASATINIB | DASATINIB | 25207766 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | IMATINIB | IMATINIB | 25207766 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565827 | | |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | inhibitor | 363894211 | PEXMETINIB | |